Table 2 Comparison of eyes with and without evident inner nuclear layer lesions
Characteristic | With INL lesions (N = 30) | Without INL Lesions (N = 39) | p-value 1 | q-value 2 | ||
|---|---|---|---|---|---|---|
95% CI | 95% CI 1 | |||||
Group, n (%) | < 0.001 | < 0.001* | ||||
RVO | 26 (86.67%) | 68–96% | 11 (28.21%) | 16–45% | ||
Control | 4 (13.33%) | 4.4–32% | 28 (71.79%) | 55–84% | ||
Age, mean (SD) | 62.27 (9.22) | 59, 66 | 58.54 (6.03) | 57, 60 | 0.061 | 0.1 |
Gender, n (%) | 0.13 | 0.2 | ||||
F | 8 (26.67%) | 13–46% | 18 (46.15%) | 30–63% | ||
M | 22 (73.33%) | 54–87% | 21 (53.85%) | 37–70% | ||
IHD, n (%) | 10 (33.33%) | 18–53% | 8 (20.51%) | 9.9–37% | 0.3 | 0.3 |
DM, n (%) | 9 (30%) | 15–50% | 7 (17.95%) | 8.1–34% | 0.3 | 0.3 |
VA LogMAR, median (range) | 0.097 (0.0–0.155) | 0.046 (0.0–0.155) | < 0.001 | < 0.001 | ||
RVO type, n (%) | < 0.001 | < 0.001* | ||||
None | 4 (13.33%) | 4.4–32% | 28 (71.79%) | 55–84% | ||
BRVO | 15 (50%) | 33–67% | 7 (17.95%) | 8.1–34% | ||
CRVO | 11 (36.67%) | 21–56% | 4 (10.26%) | 3.3–25% | ||